These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28910299)

  • 1. Access to benznidazole for Chagas disease in the United States-Cautious optimism?
    Alpern JD; Lopez-Velez R; Stauffer WM
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005794. PubMed ID: 28910299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
    Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain.
    Navarro M; Norman FF; Pérez-Molina JA; López-Vélez R
    Am J Trop Med Hyg; 2012 Sep; 87(3):489-90. PubMed ID: 22826485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to care for Chagas disease in the United States: a health systems analysis.
    Manne-Goehler J; Reich MR; Wirtz VJ
    Am J Trop Med Hyg; 2015 Jul; 93(1):108-13. PubMed ID: 25986581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.
    Pinheiro E; Brum-Soares L; Reis R; Cubides JC
    Rev Soc Bras Med Trop; 2017; 50(3):296-300. PubMed ID: 28700045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.
    Alonso-Padilla J; Cortés-Serra N; Pinazo MJ; Bottazzi ME; Abril M; Barreira F; Sosa-Estani S; Hotez PJ; Gascón J
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):145-157. PubMed ID: 30712412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America].
    Chaves GC; Abi-Saab Arrieche M; Rode J; Mechali D; Reis PO; Alves RV; Stobbaerts E; Aguilar NG; Ribeiro I
    Rev Panam Salud Publica; 2017 Jun; 41():e45. PubMed ID: 28614468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Approaches for the Treatment of Chagas Disease.
    Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
    Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vouching for access.
    Nat Med; 2016 Jul; 22(7):693. PubMed ID: 27387878
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
    Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
    Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.
    Perez-Zetune V; Bialek SR; Montgomery SP; Stillwaggon E
    Am J Trop Med Hyg; 2020 May; 102(5):1086-1089. PubMed ID: 32100696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spanish group defeats Shkreli in Chagas voucher race.
    Melton L
    Nat Biotechnol; 2017 Nov; 35(11):1003. PubMed ID: 29121016
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on nifurtimox for treatment of Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2021 Apr; 57(4):251-263. PubMed ID: 33851689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.